SzeYu Tong

SzeYu Tong has been working in various roles since 2020. In 2020, they were an Intern at Fapon Biotech Inc., where they participated in developing COVID-19 antibodies for antigen lateral flow testing. They were also an Assistant Investment Manager Intern at Triwise Capital and a Software Engineer Intern at ShenZhen StarCare Innovation Technology Co., where they designed a device to test the viscidity of ECG paster, wrote computer programs to select patients with common electro-cardiac traits, and manipulated the technique of analyzing basic electrocardiograms. In 2021, they became a Member of Emory EMS, an Intern at the National Innovation Center for Advanced Medical Devices, and a Research Assistant at CaseWestern Reserve University School of Medicine, where they worked on a project to utilize genomic/transcriptomic features from mitochondria to predict the drug sensitivity/metastatic potential. They also worked as an Undergraduate Research Assistant at Emory University, where they identified high copy suppressors of H3G34 Mutants. In 2022, they began working as a Principal Scientist at Adlai Nortye USA Inc.

SzeYu Tong has a diverse educational background. SzeYu began their educational journey at Sendelta International Academy, where they earned their High School Diploma in 2020. SzeYu then attended Case Western Reserve University, graduating with a Bachelor of Engineering in Biomedical/Medical Engineering in 2021. SzeYu is currently pursuing their Bachelor of Science in Computer Science at Emory University, which they are expected to complete in 2024.